The UK and US have announced a key trade agreement that will ensure no import taxes on British drug products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to increase expenditure on medicines through the National Health Service (NHS). This pledge secures that import taxes on these crucial exports will remain at nothing for a timeframe of the next three years.
This deal follows recent warnings to significantly raise tariffs on branded drug imports, with potential rates discussed reaching 100%.
"This agreement with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," a release said.
Economic Importance
Medicines are one of the the United Kingdom's most significant goods shipped to the US, which is clearly the biggest buyer for leading British pharmaceutical firms.
Trade data reveal that in the 12 months prior to last September, the UK sold medicines totaling £11.1bn to the US. This value made up a significant portion of British export trade in that timeframe.
"This guarantee secures employment, increases capital expenditure and facilitates the UK to establish itself as a worldwide center for life sciences," a government official commented.
Detailed UK Commitments
The pact entails several key pledges from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to increase overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. Last year, repayments exceeded twenty percent.
Industry Background
This agreement follows a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by assertions that US customers were paying significantly more for the identical medicines than patients in the other developed nations.
Recently, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official acknowledged that the NHS had to spend more on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the previous ten-year period.
